Similar articles

• Vaccination with FimH adhesin protects cynomolgus monkeys from colonization and infection by uropathogenic Escherichia coli.

  Langermann S, Möllby R, Burlein JE, Palaszynski SR, Auguste CG, DeFusco A, Strouse R, Schenerman MA, Hultgren SJ, Pinkner JS, Winberg J, Guldevall L, Söderhäll M, Ishikawa K, Normark S, Koenig S. Langermann S, et al. J Infect Dis. 2000 Feb;181(2):774-8. doi: 10.1086/315258. J Infect Dis. 2000. PMID: 10669375
• Prevention of mucosal Escherichia coli infection by FimH-adhesin-based systemic vaccination.

  Langermann S, Palaszynski S, Barnhart M, Auguste G, Pinkner JS, Burlein J, Barren P, Koenig S, Leath S, Jones CH, Hultgren SJ. Langermann S, et al. Science. 1997 Apr 25;276(5312):607-11. doi: 10.1126/science.276.5312.607. Science. 1997. PMID: 9110982
• Vaccination utilizing the FimCH complex as a strategy to prevent Escherichia coli urinary tract infections.

  Langermann S, Ballou WR Jr. Langermann S, et al. J Infect Dis. 2001 Mar 1;183 Suppl 1:S84-6. doi: 10.1086/318857. J Infect Dis. 2001. PMID: 11171023 Review. No abstract available.
• Transurethral instillation with fusion protein MrpH.FimH induces protective innate immune responses against uropathogenic Escherichia coli and Proteus mirabilis.

  Habibi M, Asadi Karam MR, Bouzari S. Habibi M, et al. APMIS. 2016 Jun;124(6):444-52. doi: 10.1111/apm.12523. Epub 2016 Feb 26. APMIS. 2016. PMID: 26918627
• Development of a recombinant FimCH vaccine for urinary tract infections.

  Langermann S, Ballou WR. Langermann S, et al. Adv Exp Med Biol. 2003;539(Pt B):635-48. doi: 10.1007/978-1-4419-8889-8_41. Adv Exp Med Biol. 2003. PMID: 15176317 Review. No abstract available.